Cleveland BioLabs Stock Price - CBLI

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 1.18 ▲ 0.05 (4.42%)
Company Name Stock Ticker Symbol Market Type
Cleveland BioLabs Inc CBLI NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.06 5.61% 1.13 1.28 1.00 1.28 1.07 00:00:07
Bid Price Ask Price Spread Spread % News
0.90 1.15 0.25 21.74% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,307 435,223 $ 1.16 $ 502,772 48,559 0.50 - 2.17
Last Trade Time Type Quantity Stock Price Currency
18:09:41 29 $ 1.15 USD

Cleveland BioLabs Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 12.77M 11.30M $ -3.61M -0.33 - 7.64M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 32.40%

more financials information »

Cleveland BioLabs News

Loading Messages....

Latest CBLI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CBLI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.021.280.701010.931701691,7240.1110.78%
1 Month0.711.280.5150.825407770,5800.4259.15%
3 Months0.651.280.500.846903855,8010.4873.85%
6 Months1.451.600.500.891047732,419-0.32-22.07%
1 Year1.502.170.501.1124,210-0.37-24.67%
3 Years1.535.550.504.05139,045-0.40-26.14%
5 Years0.26037.240.194.04137,0700.8697334.11%

Cleveland BioLabs Description

Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and an immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.